Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ:ABVX) with a Market Outperform and maintains $187 price target.
Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ:ABVX) with a Market Outperform and maintains $187 price target.